MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis

Microbes and Infection

Volumn 8, Issue 3, 2006, Pages 810-822

  Pérez Jiménez, Eva ^a   Kochan, Grazyna ^a   Gherardi, M Magdalena ^a   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Cutaneous; Leishmaniasis; Poxvirus vectors; Prime boost; Vaccination

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; RECOMBINANT LACK PROTEIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; CD4 LYMPHOCYTE PERCENTAGE; CD8+ T LYMPHOCYTE; CLINICAL PROTOCOL; CONTROLLED STUDY; EXPERIMENTAL INFECTION; FEMALE; IMMUNOGENICITY; INFECTION PREVENTION; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LYMPHOCYTE ACTIVATION; MODIFIED VACCINIA VIRUS ANKARA; MOUSE; NONHUMAN; PARASITEMIA; POXVIRUS; PRIORITY JOURNAL; SKIN LEISHMANIASIS; SPECIES COMPARISON; SPLEEN CELL; TH1 CELL; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIGENS, PROTOZOAN; DNA, PROTOZOAN; DRUG ADMINISTRATION SCHEDULE; FEMALE; IMMUNIZATION, SECONDARY; INTERFERON TYPE II; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC; VACCINIA VIRUS;

ANIMALIA; ANKARA; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; POXVIRIDAE; VACCINIA VIRUS;

EID: 33646072495     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2005.10.004     Document Type: Article

References (68)

1. World Health Organization, Leishmania/HIV Co-infection in South-Western Europe 1990-1998: Retrospective Analysis of 965 Cases, Geneve, WHO/LEISH/2000 42 (2000) 1-12.
2. Lopez-Velez R., Perez-Molina J.A., Guerrero A., Baquero F., Villarrubia J., Escribano L., Bellas C., Perez-Corral F., and Alvar J. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am. J. Trop. Med. Hyg. 58 (1998) 436
3. Berrahal F., Mary C., Roze M., Berenger A., Escoffier K., Lamouroux D., and Dunan S. Canine leishmaniasis: identification of asymptomatic carriers by polymerase chain reaction and immunoblotting. Am. J. Trop. Med. Hyg. 55 (1996) 273
4. Solano-Gallego L., Llull J., Ramos G., Riera C., Arboix M., Alberola J., and Ferrer L. The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection. Vet. Parasitol. 90 (2000) 37
5. Ponte-Sucre A. Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplastid Biol. Dis. 2 (2003) 14
6. Carter K.C., Sundar S., Spickett C., Pereira O.C., and Mullen A.B. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrob. Agents Chemother. 47 (2003) 1529
7. Ghosh S., Goswami S., and Adhya S. Role of superoxide dismutase in survival of Leishmania within the macrophage. Biochem. J. 369 (2003) 447
8. Ahmed S.B., Bahloul C., Robbana C., Askri S., and Dellagi K. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine 22 (2004) 1631
9. Mougneau E., Altare F., Wakil A.E., Zheng S., Coppola T., Wang Z.E., Waldmann R., Locksley R.M., and Glaichenhaus N. Expression cloning of a protective Leishmania antigen. Science 268 (1995) 563
10. Julia V., and Glaichenhaus N. CD4 (+) T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10.D2 mice. Infect. Immun. 67 (1999) 3641
11. Afonso L.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchieri G., and Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263 (1994) 235
12. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., and Seder R.A. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186 (1997) 1137
13. Moll H., Scollay R., and Mitchell G.F. Resistance to cutaneous leishmaniasis in nude mice injected with L3T4+T cells but not with Ly-2+T cells. Immunol. Cell Biol. 66 Pt 1 (1988) 57
14. Herath S., Kropf P., and Muller I. Cross-talk between CD8 (+) and CD4 (+) T cells in experimental cutaneous leishmaniasis: CD8 (+) T cells are required for optimal IFN-gamma production by CD4 (+) T cells. Parasite Immunol. 25 (2003) 559
15. Belkaid Y., Von Stebut E., Mendez S., Lira R., Caler E., Bertholet S., Udey M.C., and Sacks D. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 168 (2002) 3992
16. Scott P., Caspar P., and Sher A. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes. J. Immunol. 144 (1990) 1075
17. Scott P., Natovitz P., Coffman R.L., Pearce E., and Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J. Exp. Med. 168 (1988) 1675
18. Holaday B.J., Sadick M.D., Wang Z.E., Reiner S.L., Heinzel F.P., Parslow T.G., and Locksley R.M. Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines. J. Immunol. 147 (1991) 1653
19. Caver T.E., Lockey T.D., Srinivas R.V., Webster R.G., and Hurwitz J.L. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine 17 (1999) 1567
20. Hanke T., and McMichael A. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol. Lett. 66 (1999) 177
21. Hanke T., Neumann V.C., Blanchard T.J., Sweeney P., Hill A.V., Smith G.L., and McMichael A. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17 (1999) 589
22. Kent S.J., Zhao A., Best S.J., Chandler J.D., Boyle D.B., and Ramshaw I.A. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72 (1998) 10180
23. Robinson H.L., Montefiori D.C., Johnson R.P., Manson K.H., Kalish M.L., Lifson J.D., Rizvi T.A., Lu S., Hu S.L., Mazzara G.P., Panicali D.L., Herndon J.G., Glickman R., Candido M.A., Lydy S.L., Wyand M.S., and McClure H.M. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5 (1999) 526
24. Sedegah M., Jones T.R., Kaur M., Hedstrom R., Hobart P., Tine J.A., and Hoffman S.L. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 7648
25. Estcourt M.J., Ramsay A.J., Brooks A., Thomson S.A., Medveckzy C.J., and Ramshaw I.A. Prime-boost immunization generates a high frequency, high-avidity CD8 (+) cytotoxic T lymphocyte population. Int. Immunol. 14 (2002) 31
26. Gonzalo R.M., del Real G., Rodriguez J.R., Rodriguez D., Heljasvaara R., Lucas P., Larraga V., and Esteban M. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 20 (2002) 1226
27. Zavala F., Rodrigues M., Rodriguez D., Rodriguez J.R., Nussenzweig R.S., and Esteban M. A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8 (+) T cells. Virology 280 (2001) 155
28. Ramshaw I.A., and Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21 (2000) 163
29. Ramiro M.J., Zarate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., Lucientes J., Castillo J.A., and Larraga V. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21 (2003) 2474
30. Tapia E., Perez-Jimenez E., Lopez-Fuertes L., Gonzalo R., Gherardi M.M., and Esteban M. The combination of DNA vectors expressing IL-12+ IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes. Infect. 5 (2003) 73
31. Sutter G., and Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug. Targets Infect. Disord. 3 (2003) 263
32. Meyer H., Sutter G., and Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72 Pt 5 (1991) 1031
33. Blanchard T.J., Alcami A., Andrea P., and Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79 Pt 5 (1998) 1159
34. Altenburger W., Suter C.P., and Altenburger J. Partial deletion of the human host range gene in the attenuated vaccinia virus MVA. Arch. Virol. 105 (1989) 15
35. Drexler I., Heller K., Wahren B., Erfle V., and Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79 Pt 2 (1998) 347
36. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10847
37. Ramirez J.C., Gherardi M.M., and Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74 (2000) 923
38. Mayr A., Stickl H., Muller H.K., Danner K., and Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism (author's transl). Zentralbl. Bakteriol. B 167 (1978) 375
39. Gonzalez-Aseguinolaza G., Taladriz S., Marquet A., and Larraga V. Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum. Eur. J. Biochem. 259 (1999) 909
40. Rodriguez J.F., Rodriguez D., Rodriguez J.R., McGowan E.B., and Esteban M. Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 1667
41. Gherardi M.M., Perez-Jimenez E., Najera J.L., and Esteban M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J. Immunol. 172 (2004) 6209
42. Chakrabarti S., Brechling K., and Moss B. Vaccinia virus expression vector: co expression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5 (1985) 3403
43. Gonzalo R.M., Rodriguez J.R., Rodriguez D., Gonzalez-Aseguinolaza G., Larraga V., and Esteban M. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes. Infect. 3 (2001) 701
44. Buffet P.A., Sulahian A., Garin Y.J., Nassar N., and Derouin F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob. Agents Chemother. 39 (1995) 2167
45. Reiner S.L., and Locksley R.M. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13 (1995) 151
46. Da-Cruz A.M., Conceicao-Silva F., Bertho A.L., and Coutinho S.G. Leishmania-reactive CD4+ and CD8+ T cells associated with cure of human cutaneous leishmaniasis. Infect. Immun. 62 (1994) 2614
47. Amaral V., Pirmez C., Goncalves A., Ferreira V., and Grimaldi Jr. G. Cell populations in lesions of cutaneous leishmaniasis of Leishmania (L.) amazonensis-infected rhesus macaques, Macaca mulatta. Mem. Inst. Oswaldo Cruz 95 (2000) 209
48. Muller I., Pedrazzini T., Kropf P., Louis J., and Milon G. Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells. Int. Immunol. 3 (1991) 587
49. Lopez-Fuertes L., Perez-Jimenez E., Vila-Coro A.J., Sack F., Moreno S., Konig S.A., Junghans C., Wittig B., Timon M., and Esteban M. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 21 (2002) 247
50. Liew F.Y., Li Y., Yang D.M., Severn A., and Cox F.E. TNF-alpha reverses the disease-exacerbating effect of subcutaneous immunization against murine cutaneous leishmaniasis. Immunology 74 (1991) 304
51. Cote-Sierra J., Bredan A., Toldos C.M., Stijlemans B., Brys L., Cornelis P., Segovia M., de Baetselier P., and Revets H. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major. Infect. Immun. 70 (2002) 240
52. Wilhelm P., Ritter U., Labbow S., Donhauser N., Rollinghoff M., Bogdan C., and Korner H. Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF. J. Immunol. 166 (2001) 4012
53. Reiner S.L., Wang Z.E., Hatam F., Scott P., and Locksley R.M. TH1 and TH2 cell antigen receptors in experimental leishmaniasis. Science 259 (1993) 1457
54. Julia V., Rassoulzadegan M., and Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science 274 (1996) 421
55. Sedegah M., Belmonte M., Epstein J.E., Siegrist C.A., Weiss W.R., Jones T.R., Lu M., Carucci D.J., and Hoffman S.L. Successful induction of CD8 T cell-dependent protection against malaria by sequential immunization with DNA and recombinant poxvirus of neonatal mice born to immune mothers. J. Immunol. 171 (2003) 3148
56. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., Vuola J.M., Blanchard T.J., Gothard P., Watkins K., Hannan C.M., Everaere S., Brown K., Kester K.E., Cummings J., Williams J., Heppner D.G., Pathan A., Flanagan K., Arulanantham N., Roberts M.T., Roy M., Smith G.L., Schneider J., Peto T., Sinden R.E., Gilbert S.C., and Hill A.V. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9 (2003) 729
57. Gomez C.E., Rodriguez D., Rodriguez J.R., Abaitua F., Duarte C., and Esteban M. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector. Vaccine 20 (2001) 961
58. Meyer R.G., Britten C.M., Siepmann U., Petzold B., Sagban T.A., Lehr H.A., Weigle B., Schmitz M., Mateo L., Schmidt B., Bernhard H., Jakob T., Hein R., Schuler G., Schuler-Thurner B., Wagner S.N., Drexler I., Sutter G., Arndtz N., Chaplin P., Metz J., Enk A., Huber C., and Wolfel T. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol. Immunother. 54 (2005) 453
59. Gurunathan S., Stobie L., Prussin C., Sacks D.L., Glaichenhaus N., Iwasaki A., Fowell D.J., Locksley R.M., Chang J.T., Wu C.Y., and Seder R.A. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J. Immunol. 165 (2000) 915
60. Rafati S., Kariminia A., Seyde-Eslami S., Narimani M., Taheri T., and Lebbatard M. Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8 (+) T lymphocyte activation. Vaccine 20 (2002) 2439
61. Rodrigues M.M., Boscardin S.B., Vasconcelos J.R., Hiyane M.I., Salay G., and Soares I.S. Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines. An. Acad. Bras. Cienc. 75 (2003) 443
62. Jankovic D., Liu Z., and Gause W.C. Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Immunol. 22 (2001) 450
63. Kemp K., Theander T.G., Hviid L., Garfar A., Kharazmi A., and Kemp M. Interferon-gamma- and tumour necrosis factor-alpha-producing cells in humans who are immune to cutaneous leishmaniasis. Scand. J. Immunol. 49 (1999) 655
64. Dondji B., Perez-Jimenez E., Goldsmith-Pestana K., Esteban M., and McMahon-Pratt D. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect. Immun. 73 (2005) 5286
65. Kaye P.M., Curry A.J., and Blackwell J.M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146 (1991) 2763
66. Miralles G.D., Stoeckle M.Y., McDermott D.F., Finkelman F.D., and Murrat H.W. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect. Immun. 62 (1994) 1058
67. Guerra S., Lopez-Fernandez S.L.A., Conde R., Pascual-Montano A., Harshman K., and Esteban M. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J. Virol. 78 (2004) 5820
68. Chen F., Castranova V., Shi X., and Demers L.M. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin. Chem. 45 (1999) 7